Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.

Gargano SM, Senarathne W, Feldman R, Florento E, Stafford P, Swensen J, Vranic S, Gatalica Z.

Cancer Med. 2019 Oct 14. doi: 10.1002/cam4.2602. [Epub ahead of print]

2.

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.

Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R.

Int J Cancer. 2019 Sep 3. doi: 10.1002/ijc.32661. [Epub ahead of print]

PMID:
31479512
3.

Detection of NRG1 Gene Fusions in Solid Tumors.

Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, Ma PC, Nieva JJ, Spira AI, Vanderwalde AM, Wozniak AJ, Kim ES, Liu SV.

Clin Cancer Res. 2019 Aug 15;25(16):4966-4972. doi: 10.1158/1078-0432.CCR-19-0160. Epub 2019 Apr 15.

PMID:
30988082
4.

NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum.

Stevens TM, Morlote D, Xiu J, Swensen J, Brandwein-Weber M, Miettinen MM, Gatalica Z, Bridge JA.

Mod Pathol. 2019 Jun;32(6):764-773. doi: 10.1038/s41379-019-0206-z. Epub 2019 Feb 5.

PMID:
30723300
5.

Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast.

Vranic S, Palazzo J, Swensen J, Xiu J, Florento E, Gatalica Z.

Breast J. 2019 Jan;25(1):175-176. doi: 10.1111/tbj.13187. Epub 2018 Dec 18. No abstract available.

PMID:
30565349
6.

Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.

Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J, Swensen J, Gatalica Z.

Clin Breast Cancer. 2019 Apr;19(2):131-136. doi: 10.1016/j.clbc.2018.09.001. Epub 2018 Sep 5.

7.

Molecular characterization of cancers with NTRK gene fusions.

Gatalica Z, Xiu J, Swensen J, Vranic S.

Mod Pathol. 2019 Jan;32(1):147-153. doi: 10.1038/s41379-018-0118-3. Epub 2018 Aug 31.

PMID:
30171197
8.

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.

Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S.

Int J Mol Sci. 2018 Jul 18;19(7). pii: E2087. doi: 10.3390/ijms19072087. Review.

9.

Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE): A Next-Generation Sequencing Study.

Stevens TM, Morlote D, Swensen J, Ellis M, Harada S, Spencer S, Prieto-Granada CN, Folpe AL, Gatalica Z.

Head Neck Pathol. 2019 Jun;13(2):162-168. doi: 10.1007/s12105-018-0927-1. Epub 2018 May 7.

10.

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.

Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. doi: 10.1093/jnen/nly022.

11.

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.

Gatalica Z, Xiu J, Swensen J, Vranic S.

Eur J Cancer. 2018 May;94:179-186. doi: 10.1016/j.ejca.2018.02.021. Epub 2018 Mar 20.

12.

Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment Options.

Stevens TM, Qarmali M, Morlote D, Mikhail FM, Swensen J, Gatalica Z, Siegal GP, Conry RM.

Int J Surg Pathol. 2018 Aug;26(5):440-447. doi: 10.1177/1066896918755009. Epub 2018 Feb 1.

PMID:
29390927
13.

Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.

Topcagic J, Feldman R, Ghazalpour A, Swensen J, Gatalica Z, Vranic S.

PLoS One. 2018 Jan 11;13(1):e0191244. doi: 10.1371/journal.pone.0191244. eCollection 2018.

14.

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.

Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS.

Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.

15.

Primary renal sclerosing epithelioid fibrosarcoma: a case report and review of the literature.

Torabi A, Corral J, Gatalica Z, Swensen J, Moraveji S, Bridge JA.

Pathology. 2017 Jun;49(4):447-450. doi: 10.1016/j.pathol.2017.01.010. Epub 2017 Apr 25. Review. No abstract available.

PMID:
28450092
16.

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB.

Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026.

17.

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.

Joneja U, Vranic S, Swensen J, Feldman R, Chen W, Kimbrough J, Xiao N, Reddy S, Palazzo J, Gatalica Z.

J Clin Pathol. 2017 Mar;70(3):255-259. doi: 10.1136/jclinpath-2016-203874. Epub 2016 Aug 16.

18.

The Splicing Efficiency of Activating HRAS Mutations Can Determine Costello Syndrome Phenotype and Frequency in Cancer.

Hartung AM, Swensen J, Uriz IE, Lapin M, Kristjansdottir K, Petersen US, Bang JM, Guerra B, Andersen HS, Dobrowolski SF, Carey JC, Yu P, Vaughn C, Calhoun A, Larsen MR, Dyrskjøt L, Stevenson DA, Andresen BS.

PLoS Genet. 2016 May 19;12(5):e1006039. doi: 10.1371/journal.pgen.1006039. eCollection 2016 May.

19.

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.

Gatalica Z, Vranic S, Xiu J, Swensen J, Reddy S.

Fam Cancer. 2016 Jul;15(3):405-12. doi: 10.1007/s10689-016-9884-6. Review.

20.

TAF1 Variants Are Associated with Dysmorphic Features, Intellectual Disability, and Neurological Manifestations.

O'Rawe JA, Wu Y, Dörfel MJ, Rope AF, Au PY, Parboosingh JS, Moon S, Kousi M, Kosma K, Smith CS, Tzetis M, Schuette JL, Hufnagel RB, Prada CE, Martinez F, Orellana C, Crain J, Caro-Llopis A, Oltra S, Monfort S, Jiménez-Barrón LT, Swensen J, Ellingwood S, Smith R, Fang H, Ospina S, Stegmann S, Den Hollander N, Mittelman D, Highnam G, Robison R, Yang E, Faivre L, Roubertie A, Rivière JB, Monaghan KG, Wang K, Davis EE, Katsanis N, Kalscheuer VM, Wang EH, Metcalfe K, Kleefstra T, Innes AM, Kitsiou-Tzeli S, Rosello M, Keegan CE, Lyon GJ.

Am J Hum Genet. 2015 Dec 3;97(6):922-32. doi: 10.1016/j.ajhg.2015.11.005.

21.

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

Wen W, Chen WS, Xiao N, Bender R, Ghazalpour A, Tan Z, Swensen J, Millis SZ, Basu G, Gatalica Z, Press MF.

J Mol Diagn. 2015 Sep;17(5):487-95. doi: 10.1016/j.jmoldx.2015.04.003.

22.

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.

Gatalica Z, Bilalovic N, Palazzo JP, Bender RP, Swensen J, Millis SZ, Vranic S, Von Hoff D, Arceci RJ.

Oncotarget. 2015 Aug 14;6(23):19819-25.

23.

Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects.

Myklebust LM, Van Damme P, Støve SI, Dörfel MJ, Abboud A, Kalvik TV, Grauffel C, Jonckheere V, Wu Y, Swensen J, Kaasa H, Liszczak G, Marmorstein R, Reuter N, Lyon GJ, Gevaert K, Arnesen T.

Hum Mol Genet. 2015 Apr 1;24(7):1956-76. doi: 10.1093/hmg/ddu611. Epub 2014 Dec 8.

24.

Noncontinuously binding loop-out primers for avoiding problematic DNA sequences in PCR and sanger sequencing.

Sumner K, Swensen JJ, Procter M, Jama M, Wooderchak-Donahue W, Lewis T, Fong M, Hubley L, Schwarz M, Ha Y, Paul E, Brulotte B, Lyon E, Bayrak-Toydemir P, Mao R, Pont-Kingdon G, Best DH.

J Mol Diagn. 2014 Sep;16(5):477-480. doi: 10.1016/j.jmoldx.2014.04.005. Epub 2014 Jul 9.

PMID:
25017792
25.

Torsional dynamics of steerable needles: modeling and fluoroscopic guidance.

Swensen JP, Lin M, Okamura AM, Cowan NJ.

IEEE Trans Biomed Eng. 2014 Nov;61(11):2707-17. doi: 10.1109/TBME.2014.2326161. Epub 2014 May 21.

26.

Electrically conductive bulk composites through a contact-connected aggregate.

Nawroj AI, Swensen JP, Dollar AM.

PLoS One. 2013 Dec 9;8(12):e82260. doi: 10.1371/journal.pone.0082260. eCollection 2013.

27.

Constitutional mismatch repair deficiency presenting in childhood as three simultaneous malignancies.

Walter AW, Ennis S, Best H, Vaughn CP, Swensen JJ, Openshaw A, Gripp KW.

Pediatr Blood Cancer. 2013 Nov;60(11):E135-6. doi: 10.1002/pbc.24613. Epub 2013 Jun 1.

PMID:
23729388
28.

Cystic fibrosis testing in a referral laboratory: results and lessons from a six-year period.

Ridge PG, Miller C, Bayrak-Toydemir P, Best DH, Mao R, Swensen JJ, Lyon E, Voelkerding KV.

J Clin Bioinforma. 2013 Jan 23;3(1):3. doi: 10.1186/2043-9113-3-3.

29.

The connectedness of packed circles and spheres with application to conductive cellular materials.

Swensen JP, Dollar AM.

PLoS One. 2012;7(12):e51695. doi: 10.1371/journal.pone.0051695. Epub 2012 Dec 20.

30.

The frequency of previously undetectable deletions involving 3' Exons of the PMS2 gene.

Vaughn CP, Baker CL, Samowitz WS, Swensen JJ.

Genes Chromosomes Cancer. 2013 Jan;52(1):107-12. doi: 10.1002/gcc.22011. Epub 2012 Sep 25.

PMID:
23012243
31.

Copy number variation and incomplete linkage disequilibrium interfere with the HCP5 genotyping assay for abacavir hypersensitivity.

Melis R, Lewis T, Millson A, Lyon E, McMillin GA, Slev PR, Swensen J.

Genet Test Mol Biomarkers. 2012 Sep;16(9):1111-4. doi: 10.1089/gtmb.2012.0115. Epub 2012 Aug 22.

PMID:
22913531
32.

Tuning the optical properties of mesoporous TiO2 films by nanoscale engineering.

Schwenzer B, Wang L, Swensen JS, Padmaperuma AB, Silverman G, Korotkov R, Gaspar DJ.

Langmuir. 2012 Jul 3;28(26):10072-81. doi: 10.1021/la301450h. Epub 2012 Jun 21.

PMID:
22662748
33.

Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency.

Rope AF, Wang K, Evjenth R, Xing J, Johnston JJ, Swensen JJ, Johnson WE, Moore B, Huff CD, Bird LM, Carey JC, Opitz JM, Stevens CA, Jiang T, Schank C, Fain HD, Robison R, Dalley B, Chin S, South ST, Pysher TJ, Jorde LB, Hakonarson H, Lillehaug JR, Biesecker LG, Yandell M, Arnesen T, Lyon GJ.

Am J Hum Genet. 2011 Jul 15;89(1):28-43. doi: 10.1016/j.ajhg.2011.05.017. Epub 2011 Jun 23. Erratum in: Am J Hum Genet. 2011 Aug 12;89(2):345.

34.

Avoidance of pseudogene interference in the detection of 3' deletions in PMS2.

Vaughn CP, Hart KJ, Samowitz WS, Swensen JJ.

Hum Mutat. 2011 Sep;32(9):1063-71. doi: 10.1002/humu.21540.

PMID:
21618646
35.

Bone resorption in syndromes of the Ras/MAPK pathway.

Stevenson DA, Schwarz EL, Carey JC, Viskochil DH, Hanson H, Bauer S, Weng HY, Greene T, Reinker K, Swensen J, Chan RJ, Yang FC, Senbanjo L, Yang Z, Mao R, Pasquali M.

Clin Genet. 2011 Dec;80(6):566-73. doi: 10.1111/j.1399-0004.2010.01619.x. Epub 2011 Jan 19.

36.

Synthesis and application of pyridine-based ambipolar hosts: control of charge balance in organic light-emitting devices by chemical structure modification.

Koech PK, Polikarpov E, Rainbolt JE, Cosimbescu L, Swensen JS, Von Ruden AL, Padmaperuma AB.

Org Lett. 2010 Dec 3;12(23):5534-7. doi: 10.1021/ol102444j. Epub 2010 Nov 5.

PMID:
21053914
37.

Sickle cell disease resulting from uniparental disomy in a child who inherited sickle cell trait.

Swensen JJ, Agarwal AM, Esquilin JM, Swierczek S, Perumbeti A, Hussey D, Lee M, Joiner CH, Pont-Kingdon G, Lyon E, Prchal JT.

Blood. 2010 Oct 14;116(15):2822-5. doi: 10.1182/blood-2010-05-284331. Epub 2010 Jul 1.

PMID:
20595515
38.

Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes.

Vaughn CP, Robles J, Swensen JJ, Miller CE, Lyon E, Mao R, Bayrak-Toydemir P, Samowitz WS.

Hum Mutat. 2010 May;31(5):588-93. doi: 10.1002/humu.21230.

PMID:
20205264
39.

Detection of large rearrangements in the cystic fibrosis transmembrane conductance regulator gene by multiplex ligation-dependent probe amplification assay when sequencing fails to detect two disease-causing mutations.

Svensson AM, Chou LS, Miller CE, Robles JA, Swensen JJ, Voelkerding KV, Mao R, Lyon E.

Genet Test Mol Biomarkers. 2010 Apr;14(2):171-4. doi: 10.1089/gtmb.2009.0099.

PMID:
20059381
40.

Integrated microfluidic electrochemical DNA sensor.

Ferguson BS, Buchsbaum SF, Swensen JS, Hsieh K, Lou X, Soh HT.

Anal Chem. 2009 Aug 1;81(15):6503-8. doi: 10.1021/ac900923e.

PMID:
19586008
41.

Continuous, real-time monitoring of cocaine in undiluted blood serum via a microfluidic, electrochemical aptamer-based sensor.

Swensen JS, Xiao Y, Ferguson BS, Lubin AA, Lai RY, Heeger AJ, Plaxco KW, Soh HT.

J Am Chem Soc. 2009 Apr 1;131(12):4262-6. doi: 10.1021/ja806531z.

42.

Familial occurrence of schwannomas and malignant rhabdoid tumour associated with a duplication in SMARCB1.

Swensen JJ, Keyser J, Coffin CM, Biegel JA, Viskochil DH, Williams MS.

J Med Genet. 2009 Jan;46(1):68-72. doi: 10.1136/jmg.2008.060152.

43.

A new genomic mechanism leading to cri-du-chat syndrome.

South ST, Swensen JJ, Maxwell T, Rope A, Brothman AR, Chen Z.

Am J Med Genet A. 2006 Dec 15;140(24):2714-20.

PMID:
17103439
44.

Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer.

Camp NJ, Swensen J, Horne BD, Farnham JM, Thomas A, Cannon-Albright LA, Tavtigian SV.

Genet Epidemiol. 2005 Apr;28(3):232-43.

PMID:
15593091
45.

Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees.

Farnham JM, Camp NJ, Swensen J, Tavtigian SV, Albright LA.

Hum Genet. 2005 Feb;116(3):179-85. Epub 2004 Dec 8.

PMID:
15592687
46.

Association of a Trp16Ser variation in the gonadotropin releasing hormone signal peptide with bone mineral density, revealed by SNP-dependent PCR typing.

Iwasaki H, Emi M, Ezura Y, Ishida R, Kajita M, Kodaira M, Yoshida H, Suzuki T, Hosoi T, Inoue S, Shiraki M, Swensen J, Orimo H.

Bone. 2003 Feb;32(2):185-90.

PMID:
12633791
47.

Association of common missense changes in ELAC2 ( HPC2) with prostate cancer in a Japanese case-control series.

Fujiwara H, Emi M, Nagai H, Nishimura T, Konishi N, Kubota Y, Ichikawa T, Takahashi S, Shuin T, Habuchi T, Ogawa O, Inoue K, Skolnick MH, Swensen J, Camp NJ, Tavtigian SV.

J Hum Genet. 2002;47(12):641-8.

PMID:
12522685
48.

A candidate prostate cancer susceptibility gene at chromosome 17p.

Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA.

Nat Genet. 2001 Feb;27(2):172-80.

PMID:
11175785
49.

Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family.

Swensen J, Hoffman M, Skolnick MH, Neuhausen SL.

Hum Mol Genet. 1997 Sep;6(9):1513-7.

PMID:
9285788
50.

Identification of a one-base germline deletion (codon 888 del C) and an intron splice acceptor site polymorphism in hMSH2.

Swensen J, Lewis CM, Cannon-Albright LA.

Hum Mutat. 1997;10(1):80-1. No abstract available.

PMID:
9222765

Supplemental Content

Loading ...
Support Center